Author

K. Ware

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

J. Somarelli· 2 shared A. Agarwal· 1 shared A. Armstrong· 1 shared A. Lazarides· 1 shared A. Nanda· 1 shared C. Eward· 1 shared D. Hsu· 1 shared D. Singh· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Somarelli

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Emergent dynamics of underlying regulatory network links EMT and androgen receptor-dependent resistance in prostate cancer

R. Jindal, A. Nanda, M. Pillai, K. Ware, D. Singh, M. Sehgal, A. Armstrong, J. Somarelli, M. K. Jolly

The paper models a regulatory network linking EMT and AR resistance in prostate cancer, identifying four phenotypes and showing stochastic switching between states.

Computational and Structural Biotechnology Journal · Jan 1, 2023Peer-reviewedCancer Biology

A cross-species drug discovery pipeline to identify and validate new treatments for osteosarcoma

J. Somarelli, G. Rupprecht, E. Altunel, E. Flamant, S. R. Rao, D. Sivaraj, A. Lazarides, S. Hoskinson, M. Sheth, S. Cheng, S. Y. Kim, K. Ware, A. Agarwal, M. Cullen, L. Selmic, , D. Hsu

This study develops a cross-species drug discovery pipeline to identify and validate new treatments for osteosarcoma, finding that dual inhibition of proteasome and CRM1 pathways induces synergistic cytotoxicity.

bioRxiv · Oct 19, 2020Cancer Biology